On March 5, 2014, Opexa Therapeutics, Inc. (NASDAQ:OPXA) entered into a First Amendment to Sales Agreement (the “First Amendment”) with Meyers Associates, L.P. (doing business as Brinson Patrick, a division of Meyers Associates, L.P.) (the “New Sales Manager”) and Brinson Patrick Securities Corporation (the “Original Sales Manager”). Pursuant to the First Amendment, the Sales Agreement dated September 6, 2012 by and between the Company and the Original Sales Manager was assigned by the Original Sales Manager to the New Sales Manager. The Sales Agreement, as amended, is referred to herein as the “ATM Agreement.” Opexa Therapeutics Inc. (NASDAQ:OPXA) stock performance was 4.89% in last session and finished the day at $1.93. Traded volume was 1.28 million shares in the last session and the average volume of the stock remained 597,432.00 shares. The beta of the stock remained 2.70. Opexa Therapeutics Inc. (NASDAQ:OPXA) insider ownership is 2.00%.
Intrexon Corporation (NYSE:XON), a leader in synthetic biology, announced the appointment of Kelly Huang, Ph.D., most recently President of HealthTronics, Inc., a subsidiary of Endo Health Solutions, to head the Company’s newly established Consumer Sector. Intrexon Corp (NYSE:XON) rose 11.46% to $30.55 yesterday on volume of 1.27 million shares. The intra-day range of the stock was $27.03 – $31.24. Intrexon Corp (NYSE:XON) has a market capitalization of 1.66 billion.
Small biotech firm Chimerix Inc. (NASDAQ:CMRX) is under increasing pressure to help a dying 7-year-old boy with an experimental drug, but is reluctant because doing so will hamper the company’s efforts to get it to market in a timely fashion. Chimerix Inc. (NASDAQ:CMRX)’s stock on March 12, 2014 reported a higher of 18.17% to the closing price of $24.58. Its fifty two weeks range is $12.96 – $27.00. The total market capitalization recorded 649.40 million. The overall volume in the last trading session was 1.29 million shares. In its share capital, Chimerix Inc. (NASDAQ:CMRX) has 26.42 million outstanding shares.
NewLink Genetics Corporation (NASDAQ:NLNK), on 11 march reported consolidated financial results for the fourth quarter and year end 2013 and reviewed key 2013 accomplishments. On Wednesday, shares of NewLink Genetics Corp (NASDAQ:NLNK) advanced 3.97% to close the day at $31.69. Company return on investment (ROI) is -91.70% and its monthly performance is recorded as -24.33%. NewLink Genetics Corp (NASDAQ:NLNK) quarterly revenue growth is 50.40%.